Shares of Novo Nordisk dropped over 24% after disappointing results in a trial for its CagriSema weight loss drug, which fell short of expectations with a 22.7% weight reduction. The stock recovered slightly to trade down 18.8%, while rival Eli Lilly’s obesity drug saw a 5% rise. Novo plans to further explore CagriSema’s potential after outperforming Wegovy in weight loss, with regulatory submission expected by 2025.
Full Article
Cold, rainy weather not over for Britons in the lead-up to spring
Milder weather has given Britons relief from recent storm damage, but the UK is cautioned to prepare for more wet and windy conditions leading up to spring, with northwestern areas likely to experience heavy rain and strong winds from 4-13 February. Southern England will see fewer weather disruptions, with periods of dry weather expected, although some rain may occur. After 14 February, brief cold spells are anticipated between weather systems, with the south facing potential...
Read more